Table 2.
Recommended procedures in processing blood samples for T cell assays.
| Step | Recommendations | Level of evidence | Major unknowns | T cell assays used for validation | References |
|---|---|---|---|---|---|
| Blood drawing | Fasting state | E | n.a. | [1–20,71,72] | |
| Same time of the day | E | Whole blood IFN-γ/IL-10 ELISA | [21,22] | ||
| Vacuum tubes or syringes | D | IFN-γ ELISPOT, class I MMrs | [23] | ||
| Sodium or lithium heparin | C | IFN-γ ELISPOT, IFN-γ ICS | [24–26] | ||
| Minimum delay in processing (8–12 h) | C | IFN-γ ELISPOT | [23,24,27–30] | ||
| Room tewmperature storage, gentle agitation | D | IFN-γ ELISPOT, class I MMrs | [23,25,29,32] | ||
| Dilution if storage > 8 h | C | IFN-γ ELISPOT, class I MMrs | [23,29] | ||
| Blood shipping | Insulated containers | B | IFN-γ ELISPOT | [33,34] | |
| PBMC preparation | Ficoll ± Leucosep® or CPT™ tubes | D | IFN-γ ELISPOT, class I MMrs | [23,36–38] | |
| Ficoll preparations? | [35] | ||||
| Washes with media containing human serum | D | IFN-γ ELISPOT, class I MMrs | [23] | ||
| Whole blood versus PBMCs? | [26,40–42] | ||||
| PBMC freezing | Freezing media? | [24,53,54] | |||
| Medium temperature? | [35,47,56] | ||||
| Caspase inhibitors? | [55] | ||||
| PBMC concentration ≤ 3 × 107/ml | E | n.a. | [53] | ||
| Cooling rate 1°C/min down to −70°C | E | n.a. | |||
| Prompt transfer to liquid nitrogen (24–72 h) | E | n.a. | [24,53] | ||
| Storage temperature ≤ −132°C (vapour or liquid nitrogen) | E | n.a. | [24,53] | ||
| PBMC shipping | Liquid nitrogen (vapour or liquid phase) | D | IFN-γ ELISPOT, IFN-γ ICS | [24] | |
| Long-term preservation | Better if < 6 months | D | IFN-γ ICS | [57] | |
| PBMC thawing | Rapid, 37°C thawing temperature | E | n.a. | [53] | |
| 15–50 ml thawing volumes | E | n.a. | [53] | ||
| 280–450 g, 5–10 min centrifugation | E | n.a. | [53] | ||
| DNase treatment if clumping | C | [3H]-TdR, cytokine ELISA | [58] | ||
| 1–12 h PBMC resting | C | IFN-γ ELISPOT | [27,46,59,60] | ||
| T cell assays | Human serum-supplemented media | E | n.a. | ||
| Serum-free media | B | IFN-γ ELISPOT | [54] | ||
| Addition of low-dose cytokines (e.g. IL-7)? | [33,34,54] | ||||
| High quality protein or peptide antigens | A | [3H]-TdR | [62–67] | ||
| Positive controls: recall antigens and polyclonal stimuli | E | n.a. |
[3H]-TdR: thymidine incorporation; ICS: intracellular cytokine staining; MMrs: human leucocyte antigen multimers; n.a.: not available; PBMC: peripheral blood mononuclear cells; IL: interleukin; IFN: interferon; ELISPOT: enzyme-linked immunospot; ELISA: enzyme-linked immunosorbent assay.